Influenza Type A and Type B
Conditions
Interventions
Test drug: Tsumura Mao-to extract granule for prescription Normal adult dose is 7.5g p.o. in 2-3 divided doses, before or between meals. Duration of administration: 5 days
Sponsors
TJ-27 Influenza study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with a fever >38.0C or >37.5C at the time of admission, or >38.0C within 4 hours of admission 2) Patients who tested positive on Rapid Influenza Diagnostic Test 3) Patients with influenza symptoms within 48 hours of onset 4) Age: between 20 - 65 y/o (at the time of acquisition of consent) 5) Gender: no specification 6) Consultation method: outpatient 7) Patients who can provide a written consent
Exclusion criteria
Exclusion criteria: 1) Patients who were taking Kampo or medication for respiratory disease within 3 days of registration 2) Patients who obtained an influenza vaccination within 2 weeks of registration 3) Patients with serious complications (liver, kidney, heart, lung, circulatory, or metabolic disorder) 4) Patients suspected of concomitant bacterial infection of the respiratory system 5) Patients with a history of drug allergy 6) Patients who are nursing, pregnant or desiring conception 7) Patients who are currently taking a test drug or planning to partake in a clinical trial 8) Patients with contraindication for acetaminophen (peptic ulcer, aspirin-induced asthma, acetaminophen hypersensitivity) 9) Patients who are considered inappropriate by the research director, research staff, or others (referred collectively as research director, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Symptoms of Influenza 1) fever clearance time 2) other symptoms (nasal discharge, nasal obstruction, sore throat, cough, muscle ache, arthralgia, lethargy or fatigue, headache) 1. Laboratory test for virus | — |
Countries
Japan
Contacts
Public ContactNorio Iwaki
Iwaki internal medicine clinic directer
Outcome results
None listed